Top 10 Trends in Medicine, August 2014

August 26, 2014

#9 Clinical Trend: Zydelig

Idelalisib (Zydelig) was recently approved by the FDA for treatment of chronic lymphocytic leukemia (CLL). It was given breakthrough therapy designation and joins obinutuzumab, ofatumumab, and ibrutinib as recently approved medications for the treatment of CLL. Idelalisib was specifically approved for use in combination with rituximab in patients with comorbidities that would require treatment with rituximab alone.

For more in-depth clinical information, see Chronic Lymphocytic Leukemia Medication.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.